RxDoctor Payments Data

Michael Yen, MD

Interventional Cardiology · Poughkeepsie, NYNPI 1356315907

Payments from drug & device makers

$1,313in general payments, 2019–2025

Across 64 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$173
  • Boston Scientific$164
  • Abiomed$142
  • Novartis$141
  • Amgen$114
  • Medtronic$107
  • plus $472 from 14 others

What the payments were for

  • Consulting fees$655%
  • Grants$272%
  • Food & beverage$1,20392%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,313 in reported general payments places this provider in the 10th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$271,480
Medicare patients
1,195
Services billed
3,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$307,834
XareltoRivaroxaban92$133,778
EntrestoSacubitril/Valsartan50$71,889
JardianceEmpagliflozin33$36,106
FarxigaDapagliflozin Propanediol18$24,052
BrilintaTicagrelor19$19,781
VascepaIcosapent Ethyl32$17,401
Repatha SyringeEvolocumab17$13,707
Praluent PenAlirocumab11$13,118
Atorvastatin Calcium789$9,587
Rosuvastatin Calcium495$7,972
Metoprolol Succinate570$7,956
NexletolBempedoic Acid11$7,189
ClopidogrelClopidogrel Bisulfate306$3,521
Losartan Potassium271$3,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$307,834231 claims
Johnson & JohnsonXarelto$50$133,77892 claims
NovartisEntresto$141$71,88950 claims
AstraZenecaFarxiga, Brilinta$173$43,83237 claims
Boehringer IngelheimJardiance$27$36,10633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →